Denonvilliers' fascia as a potential nerve-course marker for the female urinary bladder
CONCLUSION: The DF can be used as a marker for nerve course, particularly in one of the bladder branches running directly superior to the DF, which can be preserved in nerve-sparing Okabayashi RH.PMID:38271772 | DOI:10.1016/j.ygyno.2024.01.025 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 25, 2024 Category: Cancer & Oncology Authors: Kenro Chikazawa Satoru Muro Kumiko Yamaguchi Ken Imai Tomoyuki Kuwata Ryo Konno Keiichi Akita Source Type: research
Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer
CONCLUSIONS: CR was substantially associated to patient outcomes in our series of gynecological cancer oligometastatic lesions. The ability to predict a CR through artificial intelligence could also drive treatment choices in the context of personalized oncology.PMID:38271773 | DOI:10.1016/j.ygyno.2024.01.023 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 25, 2024 Category: Cancer & Oncology Authors: Gabriella Macchia Savino Cilla Donato Pezzulla Maura Campitelli Concetta Laliscia Roberta Lazzari Lorena Draghini Andrei Fodor Giuseppe R D'Agostino Donatella Russo Vittoria Balcet Martina Ferioli Lisa Vicenzi Arcangela Raguso Vanessa Di Cataldo Elisabett Source Type: research
How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations
Gynecol Oncol. 2024 Jan 24;184:8-15. doi: 10.1016/j.ygyno.2024.01.008. Online ahead of print.ABSTRACTDespite dedicated efforts to improve equitable access to cancer care in the United States, disparities in cancer outcomes persist, and geographically underserved patients remain at an increased risk of cancer with lower rates of survival. The critical evaluation of cancer prevention inequities and clinical trial access presents the opportunity to outline novel strategies to incrementally improve bookended access to gynecologic cancer care for geographically underserved patients. Cancer prevention strategies that can be addr...
Source: Gynecologic Oncology - January 25, 2024 Category: Cancer & Oncology Authors: Kari L Ring Linda R Duska Source Type: research
Trachelectomy and fertility-sparing procedures for early-stage cervical cancer: A state of the science review
Gynecol Oncol. 2024 Jan 24;181:179-182. doi: 10.1016/j.ygyno.2024.01.014. Online ahead of print.NO ABSTRACTPMID:38271868 | DOI:10.1016/j.ygyno.2024.01.014 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 25, 2024 Category: Cancer & Oncology Authors: Beryl Manning-Geist Magdalena Alioto Grace Yukio Sonoda Source Type: research
Reviving peritoneal cytology: Exploring its role in endometrial cancer molecular classification
CONCLUSION: Positive peritoneal cytology is associated with worse oncologic outcomes in NSMP and p53abn endometrial cancer and remains an independent predictor of recurrence and death in patients with p53abn endometrial cancer.PMID:38266401 | DOI:10.1016/j.ygyno.2024.01.006 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 24, 2024 Category: Cancer & Oncology Authors: Anna-Sophie Villiger Selma Zurbriggen Sara Imboden Wiebke Solass Lucine Christe Flurina A M Saner Andrea Gm ür Tilman T Rau Michael D Mueller Franziska Siegenthaler Source Type: research
UCHL-3 as a potential biomarker of ovarian cancer
CONCLUSION: UCHL3 overexpression contributes to aggressive progression, poor survival, and chemoresistance in OC. Therefore, UCHL3 may be a candidate prognostic biomarker and potential target for controlling progression and platinum resistance in OC.PMID:38266402 | DOI:10.1016/j.ygyno.2023.12.031 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 24, 2024 Category: Cancer & Oncology Authors: Qilian Yang Xue Peng Zheng Nian Shuang Yuan Zhaoyun Wang Yuelin Song Rehim Shamsnur Hongjing Wang Tao Yi Source Type: research
A personalized probabilistic approach to ovarian cancer diagnostics
CONCLUSIONS: An integrative approach using metabolomic profiles and machine learning-based classifiers has been employed to develop a clinical tool that assigns a probability that an individual patient does or does not have ovarian cancer. This personalized/probabilistic approach to cancer diagnostics is more clinically informative and accurate than traditional binary (yes/no) tests and represents a promising new direction in the early detection of ovarian cancer.PMID:38266403 | DOI:10.1016/j.ygyno.2023.12.030 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 24, 2024 Category: Cancer & Oncology Authors: Dongjo Ban Stephen N Housley Lilya V Matyunina L DeEtte McDonald Victoria L Bae-Jump Benedict B Benigno Jeffrey Skolnick John F McDonald Source Type: research
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FR α-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
CONCLUSION: MIRV and gemcitabine demonstrate promising activity in platinum resistant EOC at RP2D, but frequent hematologic toxicities.PMID:38262235 | DOI:10.1016/j.ygyno.2023.12.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Mihaela C Cristea Daphne Stewart Timothy Synold Nora Ruel Joanne Mortimer Edward Wang Alexander Jung Sharon Wilczynski Gottfried E Konecny Melissa Eng Lindsay Kilpatrick Ernest Han Thanh Dellinger Amy Hakim Stephen Lee Robert J Morgan Mark T Wakabayashi P Source Type: research
Guideline concordant care for patients with locally advanced cervical cancer by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis
CONCLUSION: Disparities exist in the receipt of standard of care treatment for cervical cancer by racial and ethnic subgroups. It is imperative to disaggregate race and ethnicity data to understand potential differences in care and tailor interventions to achieve health equity.PMID:38262236 | DOI:10.1016/j.ygyno.2023.12.026 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Sarah S Lee Heather T Gold Simona C Kwon Bhavana Pothuri Michelle D S Lightfoot Source Type: research
Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State
CONCLUSIONS: Centralizing cytoreductive surgery for OC to high-volume centers in New York would increase patient travel burden by negligible amounts of distance and time for most patients.PMID:38262237 | DOI:10.1016/j.ygyno.2024.01.004 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Ryan M Kahn Xiaoyue Ma Sushmita Gordhandas Effi Yeoshoua Ryan J Ellis Xiuling Zhang Emeline M Aviki Nadeem R Abu-Rustum Ginger J Gardner Yukio Sonoda Oliver Zivanovic Kara Long Roche Elizabeth Jewell Thomas Boerner Dennis S Chi Source Type: research
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance
CONCLUSIONS: Using pegylated liposomal doxorubicin as part of a platinum doublet preceding maintenance PARPi for platinum-sensitive recurrence does not seem to hasten PARPi resistance or platinum resistance compared to OPDs. Although there was a non-significant trend towards increased OS among patients who received a platinum doublet other than CD prior to PARPi, the OS from PARPi start was similar between groups. Given the retrospective nature of this study and small study population, further research is needed to evaluate if the choice of platinum doublet preceding PARPi maintenance impacts PARPi resistance, platinum res...
Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Monica D Levine Heather Wang Bhargavi Sriram Ambar Khan Leigha Senter Eric M McLaughlin Kristin L Bixel Laura M Chambers David E Cohn Larry J Copeland Casey M Cosgrove Christa I Nagel David M O'Malley Floor J Backes Source Type: research
Distribution and prognostic role of BRCA status in elderly ovarian cancer patients
CONCLUSIONS: Elderly patients experiment a poorer prognosis due to multiple factors that include both their medical condition and comorbidities, under-treatment and most importantly disease characteristics. We found that beyond disparities, BRCA mutation is still the strongest independent prognostic factor affecting both the risk of recurrence and death due to disease.PMID:38262239 | DOI:10.1016/j.ygyno.2023.12.022 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Lucia Tortorella Serena Cappuccio Diana Giannarelli Camilla Nero Claudia Marchetti Valerio Gallotta Barbara Costantini Tina Pasciuto Angelo Minucci Anna Fagotti Giovanni Scambia Source Type: research
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies
CONCLUSION: Incorporating ctDNA monitoring along with traditional known risk factors may aid in identifying patients with stage I EC who are at highest risk of recurrence, and possibly aid in treatment stratification.PMID:38262240 | DOI:10.1016/j.ygyno.2023.12.025 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Fernando Recio Carly Bess Scalise Paul Loar Melissa Lumish Tara Berman Abhinand Peddada Ekaterina Kalashnikova Samuel Rivero-Hinojosa Tricia Beisch Brittany Nicosia Tiffany Farmer Punashi Dutta Meenakshi Malhotra Adam C ElNaggar Minetta C Liu Luis Vaccare Source Type: research
Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy
CONCLUSION: For patients with recurrent pMMR endometrial cancer Lenvatinib plus pembrolizumab is associated with greater survival but is more costly than chemotherapy. The cost of lenvatinib and pembrolizumab would have to be reduced by approximately 7% to be considered cost-effective.PMID:38262241 | DOI:10.1016/j.ygyno.2023.12.027 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Shayan Dioun Ling Chen Alexandre Buckley De Meritens Caryn M St Clair June Y Hou Fady Khoury-Collado Tarah Pua Dawn L Hershman Jason D Wright Source Type: research
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
CONCLUSIONS: We observed a low response rate to zanidatamab in recurrent HER2+ endometrial carcinoma/carcinosarcoma, which may be driven by downregulation of HER2 expression. Repeat HER2 testing should be considered prior to second-line HER2-directed therapy.CLINICALTRIALS: govidentifier: NCT04513665.PMID:38262242 | DOI:10.1016/j.ygyno.2023.12.028 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Melissa Lumish M Herman Chui Qin Zhou Alexia Iasonos Debra Sarasohn Seth Cohen Claire Friedman Rachel Grisham Jason Konner Chrisann Kyi Maria Rubinstein Tiffany Troso-Sandoval Carol Aghajanian Vicky Makker Source Type: research
